Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features-Reference-Cited by-同舟云学术

Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features

Published:2024-03-19 Issue: Volume: Page:
ISSN:1359-4184
Container-title:Molecular Psychiatry
language:en
Short-container-title:Mol Psychiatry

Author:

Kim Helena K.,Voineskos Aristotle N.^ORCID,Neufeld Nicholas H.^ORCID,Alexopoulos George S.^ORCID,Bingham Kathleen S.,Flint Alastair J.,Marino Patricia,Rothschild Anthony J.,Whyte Ellen M.,Mulsant Benoit H.^ORCID

Funder

Fondation Brain Canada

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre

Foundation for the National Institutes of Health

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health

Canada Foundation for Innovation

University of Toronto

Patient-Centered Outcomes Research Institute

Ontario Brain Institute

Alzheimer's Association

Allergan

Janssen Biotech

Takeda Medical Research Foundation

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41380-024-02523-7.pdf

Reference24 articles.

1. Gournellis R, Tournikioti K, Touloumi G, Thomadakis C, Michalopoulou PG, Michopoulos I, et al. Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. Ann Gen Psychiatry. 2018;17:39.

2. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73:486–96.

3. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019;322:622–31.

4. Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, et al. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020;77:674–83.

5. Ismail M, Straubinger T, Uchida H, Graff-Guerrero A, Nakajima S, Suzuki T, et al. MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. Br J Clin Pharmacol. 2022;88:3341–50.